Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Brotschi

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Chemical Communications (Cambridge, England)|April 19, 2005
RNA duplexes with biphenyl substituents as base replacements are less stable than DNA duplexesChristine Brotschi, Christian J Leumann
Nucleosides, Nucleotides & Nucleic Acids|October 21, 2003
Transition metal ligands as novel DNA-base substitutesChristine Brotschi, Christian J Leumann
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 17, 2005
pentafluorophenyl-phenyl interactions in biphenyl-DNAAlain Zahn, Christine Brotschi, Christian J Leumann
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 3, 2005
Bipyridyl- and biphenyl-DNA: a recognition motif based on interstrand aromatic stackingChristine Brotschi, Gérald Mathis, Christian J Leumann
Proceedings of the National Academy of Sciences of the United States of America|July 3, 2009
A tethering mechanism for length control in a processive carbohydrate polymerizationJohn F May, Rebecca A Splain, Christine Brotschi, et al.
RSC Medicinal Chemistry|January 29, 2024
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in ratsChristine Brotschi, Martin H Bolli, John Gatfield, et al.
Journal of Medicinal Chemistry|February 8, 2024
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical TrialsJodi T Williams, Martin H Bolli, Christine Brotschi, et al.
Journal of Medicinal Chemistry|February 13, 2024
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic DiseasesCyrille Lescop, Magdalena Birker, Christine Brotschi, et al.
Chemmedchem|May 9, 2019
Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in RatsChristine Brotschi, Catherine Roch, John Gatfield, et al.
Chemmedchem|January 17, 2020
From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in DogsChristine Brotschi, Martin H Bolli, John Gatfield, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Chemical Communications (Cambridge, England)|April 19, 2005
RNA duplexes with biphenyl substituents as base replacements are less stable than DNA duplexesChristine Brotschi, Christian J Leumann
Nucleosides, Nucleotides & Nucleic Acids|October 21, 2003
Transition metal ligands as novel DNA-base substitutesChristine Brotschi, Christian J Leumann
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 17, 2005
pentafluorophenyl-phenyl interactions in biphenyl-DNAAlain Zahn, Christine Brotschi, Christian J Leumann
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 3, 2005
Bipyridyl- and biphenyl-DNA: a recognition motif based on interstrand aromatic stackingChristine Brotschi, Gérald Mathis, Christian J Leumann
Proceedings of the National Academy of Sciences of the United States of America|July 3, 2009
A tethering mechanism for length control in a processive carbohydrate polymerizationJohn F May, Rebecca A Splain, Christine Brotschi, et al.
RSC Medicinal Chemistry|January 29, 2024
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in ratsChristine Brotschi, Martin H Bolli, John Gatfield, et al.
Journal of Medicinal Chemistry|February 8, 2024
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical TrialsJodi T Williams, Martin H Bolli, Christine Brotschi, et al.
Journal of Medicinal Chemistry|February 13, 2024
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic DiseasesCyrille Lescop, Magdalena Birker, Christine Brotschi, et al.
Chemmedchem|May 9, 2019
Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in RatsChristine Brotschi, Catherine Roch, John Gatfield, et al.
Chemmedchem|January 17, 2020
From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in DogsChristine Brotschi, Martin H Bolli, John Gatfield, et al.
Pageof 2